Having a rapid diagnostic response test kit for COVID-19 and all of it’s variants, delivering results in under 1-minute, that is highly accurate, saliva-based (non-invasive) and easy to use, enables our economy to recover from the pandemic with confidence. Having a platform that can easily and quickly be tailored for future viruses or the next pandemic is critical.
GLCM’s Biosensor Platform delivers a solution to the medical diagnostic industry offering a repeatable, consistent solution and can be tailored to detect multiple viruses and other pathogens and represents a global breakthrough in medical diagnostics by providing real-time virus detection that is unmatched in terms of sensitivity, simplicity, and reproducibility by utilizing electrochemical impedance spectroscopy (EIS). Successful implementation of the EIS method, which has been researched over decades as a desirable method of testing, is a breakthrough for GLCM and the medical diagnostics industry.
GLCM is seeking strategic partners to advance this technology into commercialization. Please email firstname.lastname@example.org for more information.